Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Precision BioSciences, Inc. (Nasdaq: DTIL) provides access to the company’s official regulatory disclosures as a clinical stage gene editing company. These documents offer detailed information on its ARCUS-based in vivo gene editing programs, financial condition, capital raising activities, and other material events relevant to shareholders and analysts.
Among the key filings are Current Reports on Form 8-K, which Precision uses to report significant developments. Examples include an 8-K describing an underwritten offering of common stock, pre-funded warrants, and warrants, with net proceeds intended to fund ongoing and planned research and development, working capital, and general corporate purposes. Other 8-Ks furnish press releases on clinical data from the ELIMINATE-B trial of PBGENE-HBV, updates on PBGENE-DMD, quarterly financial results, and executive employment arrangements.
Filings related to PBGENE-HBV summarize clinical findings such as dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), biopsy evidence of ARCUS-mediated viral DNA editing, and safety data across multiple cohorts. These reports help readers understand how Precision evaluates safety, efficacy, and dosing strategy for its hepatitis B program. Additional disclosures describe regulatory designations, trial expansion plans, and the structure of ongoing Phase 1/2a studies.
For capital markets activity, SEC filings detail the terms of equity offerings, including the number of shares and warrants issued, exercise prices, and intended use of proceeds. Exhibits to these filings may include underwriting agreements, warrant forms, and legal opinions on the validity of securities.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly grasp the implications of new 8-Ks and other reports. Real-time updates from EDGAR, combined with structured access to items such as clinical trial updates, financing transactions, and governance changes, make this page a focused resource for reviewing Precision BioSciences’ regulatory history and ongoing obligations.
Precision BioSciences furnished an update on its ELIMINATE-B Phase 1 study of PBGENE-HBV and announced related webcast details. As of
Cohort 1 included a patient with a durable ~
Precision BioSciences (DTIL)November 2, 2025, 3,605 RSUs vested and settled, resulting in the acquisition of 3,605 common shares at $0. On November 3, 2025, he sold 1,303 shares at $6.49 under a Rule 10b5-1 plan as a sell-to-cover for tax withholding tied to the RSU vesting. Following these transactions, he beneficially owns 77,298 shares.
Precision BioSciences (DTIL) reported an insider transaction by General Counsel and Secretary Dario Scimeca on a Form 4. On November 2, 2025, 1,835 RSUs vested (code M) and converted into common stock at $0. On November 3, 2025, 665 shares were sold at $6.49 in a sell-to-cover for taxes under a Rule 10b5-1 plan adopted September 29, 2025. Following these transactions, the reporting person beneficially owned 28,258 shares directly. The holdings figure includes 2,088 shares acquired via the 2019 ESPP at a weighted average price of $4.26.
Precision BioSciences (DTIL) reported an insider equity transaction by President & CEO and Director Michael Amoroso. On November 2, 2025, 9,444 RSUs vested and settled into common stock at $0 per unit, reflecting standard RSU settlement mechanics.
On November 3, 2025, Amoroso sold 3,409 shares at $6.49 per share under a Rule 10b5-1 plan adopted on August 2, 2024. The filing states this was a sell-to-cover transaction to satisfy tax withholding tied to the RSU vesting. Following these transactions, Amoroso beneficially owned 115,575 shares directly. No derivative securities remained after settlement.
Precision BioSciences (DTIL) filed its Q3 2025 10-Q, reporting continued investment in ARCUS gene editing programs and a wider net loss. Quarterly revenue was $13 thousand, reflecting lower billable work under the Novartis collaboration. Operating loss was $20.7 million and net loss was $21.8 million. Cash and cash equivalents were $44.9 million, with restricted cash of $26.3 million; total cash, cash equivalents and restricted cash were $71.2 million as of September 30, 2025.
The balance sheet shows total liabilities of $76.9 million, including a $22.5 million term loan and $26.2 million in deferred revenue, and stockholders’ equity of $16.6 million. A warrant liability was $4.0 million. Shares outstanding were 12,082,665 as of September 30, 2025, and 13,256,751 as of October 29, 2025.
PBGENE-HBV advanced with Cohort 3 dosing in the ELIMINATE-B trial, while PBGENE-DMD moved toward an anticipated U.S. IND filing by year-end 2025 after receiving Rare Pediatric Disease and Orphan Drug designations. Subsequent events included an $8.0 million milestone from Imugene on October 31, 2025 (paid as $3.0 million cash and $5.0 million stock) and Novartis’ notice to terminate the collaboration effective January 30, 2026.
Precision BioSciences, Inc. furnished an update on its financials, announcing results for the quarter ended September 30, 2025. The company disclosed the information under Item 2.02 and provided the full details via a press release.
The press release is included as Exhibit 99.1, which is incorporated by reference. The company’s common stock trades on the Nasdaq Capital Market under the symbol DTIL.
Stanley R. Frankel, a director of Precision BioSciences, Inc. (DTIL), purchased 2,700 shares of the company's common stock on 09/26/2025 at a reported price of $4.97 per share. After this transaction he beneficially owned 16,778 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact, Dario Scimeca. The filing identifies Frankel's address as c/o Precision BioSciences in Durham, North Carolina, and indicates the report was filed by one reporting person. No derivative transactions, amendments, or other securities activity are reported on this Form 4.
Precision BioSciences director Melinda Brown made an open-market purchase of company stock on 09/22/2025. She acquired 1,400 shares of Common Stock at a price of $4.89 per share, increasing her direct beneficial ownership to 21,965 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Brown on 09/24/2025. The filing identifies Ms. Brown as a director and indicates this Form 4 was filed by one reporting person. No derivative transactions or other securities classes are reported on this form.
Precision BioSciences, Inc. updated employment agreements for its key Section 16 officers, including the CEO, CFO, General Counsel, and Chief Research Officer, to support executive retention.
The amended agreements align terms with each executive’s current base salary and target bonus, change cash severance to lump-sum payments, and add protections for terminations without cause in connection with a defined change in control or restructuring event. They also provide for additional expense coverage.
To secure these obligations, the company established escrow arrangements with JPMorgan Chase Bank, N.A., funding severance and expense amounts in dedicated accounts. Interest on the escrowed funds and any unused balances revert to Precision BioSciences.
Precision BioSciences Schedule 13G/A shows that Readout-affiliated entities and Matthew Smith reported collective beneficial ownership of up to 1,119,311 shares of the issuer's common stock as of June 30, 2025, representing approximately 9.4% of the outstanding class. The filing breaks ownership across Readout Capital, Readout Capital GP, ROC Holdings SPV II, Readout Holdings GP and Matthew Smith, and discloses that ROC SPV II directly held 686,437 shares plus warrants exercisable into 220,000 shares. Readout Capital also manages a separate account holding 200,000 shares under an investment management agreement. Signatures certify the disclosures.